The pathogenesis of B-cell non-hodgkin lymphoma associated with HBV (hepatitis B virus) infection is regulated by c-Myc/PD-L1 signaling pathway

Abstract

Background HBV is closely associated with the incidence of B-NHL (B-cell non-hodgkin lymphoma). This project intends to establish HBV infection-induced B-NHL cells and animal models to clarify the mutual mechanism of HBV infection and B-NHL pathogenesis.

Methods The relationship between HBV and B-NHL was studied based on the HBV infection model, which included CTC cells and HBV transgenic mice. Moreover, differential expression analysis of transcriptome profiling was performed to confirm the mechanism.

Results The HBsAg expression and HBV-DNA could be found in tumor tissues of HBV group, but negative in the control group. Moreover, there were clearly differences between the two groups in the transcriptome of tumor tissues and CTC. HBsAg significantly promoted lymphocytes associated with c-Myc and PD-L1.

Conclusion The promoted effect induced by HBsAg in lymphocytes was associated with PD-L1 mediated by c-Myc.

Keywords

B-NHL (B cell non-Hodgkin’s lymphoma) / HBV (Hepatitis B virus) / C-Myc / PD-L1 / Transcriptome / Circulating tumor cell (CTC)

Funding

Hainan Natural Science Foundation of China (No. 817351).

Declaration of Competing Interest

The authors declare that there is no conflict of interest.

Acknowledgements

None.

References

[1] K.R. Shankland, J.O. Armitage, B.W. Hancock, Non-Hodgkin lymphoma, Lancet 380 (2012) 848-857.

[2] D.A. Arber, A. Orazi, R. Hasserjian, J. Thiele, M.J. Borowitz, M.M. Le Beau, C.D. Bloomfield, M. Cazzola, J.W. Vardiman, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood 127 (2016) 2391-2405.

[3] D.A. Eichenauer, I. Becker, I. Monsef, N. Chadwick, V. de Sanctis, M. Federico, C. Fortpied, A.M. Gianni, M. Henry-Amar, P. Hoskin, P. Johnson, S. Luminari, M. Bellei, A. Pulsoni, M.R. Sydes, P. Valagussa, S. Viviani, A. Engert, J. Franklin, Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials, Haematologica 102 (2017) 1748-1757.

[4] E.S. Jaffe, Diagnosis and classification of lymphoma: impact of technical advances, Semin. Hematol. 56 (2019) 30-36.

[5] K. Basso, R. Dalla-Favera, Germinal centres and B cell lymphomagenesis, Nat. Rev. Immunol. 15 (2015) 172-184.

[6] R. Küppers, Mechanisms of B-cell lymphoma pathogenesis, Nat. Rev. Cancer 5 (2005) 251-262.

[7] B.C. Chiu, N. Hou, Epidemiology and etiology of non-hodgkin lymphoma, Cancer Treat. Res. 165 (2015) 1-25.

[8] C.E. Huang, Y.H. Yang, Y.Y. Chen, J.J. Chang, K.J. Chen, C.H. Lu, K.D. Lee, P.C. Chen, C.C. Chen, The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma, J. Viral Hepat. 24 (2017) 885-894.

[9] M. Li, Y. Gan, C. Fan, H. Yuan, X. Zhang, Y. Shen, Q. Wang, Z. Meng, D. Xu, H. Tu, Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta- analysis of 58 studies, J. Viral. Hepat. 25 (2018) 894-903.

[10] T. Tian, C. Song, L. Jiang, J. Dai, Y. Lin, X. Xu, C. Yu, Z. Ge, Y. Ding, Y. Wen, B. Liu, Y. Shao, P. Shi, C. Zhu, Y. Liu, S. Jing, Z. Wang, Z. Hu, J. Li, Hepatitis B virus infection and the risk of cancer among the Chinese population, Int. J. Cancer 147 (2020) 3075-3084.

[11] M. Lemaitre, P. Brice, M. Frigeni, O. Hermine, L. Arcaini, C. Thieblemont, C. Besson, Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: clinical characteristics and prognosis, J. Infect. 80 (2020) 219-224.

[12] X. Zhou, P. Wuchter, G. Egerer, M. Kriegsmann, F.K.F. Kommoss, M. Witzens-Harig, K. Kriegsmann, Serological hepatitis B virus (HBV) activity in patients with HBV infection and B-cell non-Hodgkin's lymphoma, Eur. J. Haematol. 104 (5) (2020) 469-475.

[13] M. Li, Y. Shen, Y. Chen, H. Gao, J. Zhou, Q. Wang, C. Fan, W. Zhang, J. Li, H. Cong, J. Gu, Y. Gan, H. Tu, Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma, Int. J. Cancer 147 (2020) 2199-2209.

[14] X. Zhou, H. Pan, P. Yang, P. Ye, H. Cao, H. Zhou, Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma, BMC Cancer 19 (2019) 477.

[15] S. Chiatamone Ranieri, M.A. Arleo, S. Trasarti, L. Bizzoni, I. Carmosino, M.L. De Luca, S. Mohamed, E. Mariggiò, E. Scalzulli, S. Rosati, D. De Benedittis, G. Colafigli, S. Pepe, M. Molica, M.C. Scamuffa, A. Di Prima, A. Ferretti, E. Baldacci, M. Mancini, C. Santoro, M. Vignetti, M. Breccia, R. Latagliata, Clinical and prognostic features of essential thrombocythemia: comparison of 2001 WHO versus 2008/ 2016 WHO criteria in a large single-center cohort, Clin. Lymphoma Myeloma Leuk. 21 (2021) e328-e333.

[16] S.H. Swerdlow, E. Campo, S.A. Pileri, N.L. Harris, H. Stein, R. Siebert, R. Advani, M. Ghielmini, G.A. Salles, A.D. Zelenetz, E.S. Jaffe, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood 127 (2016) 2375-2390.

[17] F.V. Chisari, C.A. Pinkert, D.R. Milich, P. Fillipi, A. McLachian, R.D. Palmiter, R.L. Brinster, A transgenic mouse model of the chronichepatitis B surface antigen carrier state, Science 230 (1985) 1157-1160.

[18] F.V. Chisari, P. Filippi, A. McLachian, D.R. Milich, M. Riggs, S. Lee, R.D. Palmiter, C.A. Pinkert, R.L. Brinster, Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice, J Virol 60 (1986) 880-887.

[19] F.V. Chisari, P. Filippi, F. Buras, A. McLachian, H. Popper, C.A. Pinkert, R.D. Palmiter, R.F. Brinster,Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenicmice, Proc. Nati. Acad. Sci. USA 84 (1987) 6909-6913.

[20] C. Alix-Panabières, K. Pantel, Circulating tumor cells: liquid biopsy of cancer, Clin. Chem. 59 (2013) 110-118.

[21] N. Aceto, M. Toner, S. Maheswaran, D.A. Haber, En route to metastasis: circulating tumor cell clusters and epithelial-to-mesenchymal transition, Trends Cancer 1 (2015) 44-52.

[22] C. Alix-Panabières, K. Pantel, Challenges in circulating tumour cell research, Nat. Rev. Cancer. 14 (2014) 623-631.

[23] D. Ennishi, A. Jiang, M. Boyle, B. Collinge, B.M. Grande, S. Ben-Neriah, C. Rushton, J. Tang, N. Thomas, G.W. Slack, P. Farinha, K. Takata, T. Miyata-Takata, J. Craig, A. Mottok, B. Meissner, S. Saberi, A. Bashashati, D. Villa, K.J. Savage, L.H. Sehn, R. Kridel, A.J. Mungall, M.A. Marra, S.P. Shah, C. Steidl, J.M. Connors, R.D. Gascoyne, R.D. Morin, D.W. Scott, Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma, J. Clin. Oncol. 37 (2019) 190-201.

[24] D. Calado, Y. Sasaki, S. Godinho, et al., The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers, Nat. Immunol. 13 (2012) 1092-1100.

[25] Y.Z. Lun, J. Cheng, Q. Chi, X.L. Wang, M. Gao, L.D. Sun, Transactivation of proto-oncogene c-Myc by hepatitis B virus transactivator MHBst167, Oncol. Lett. 8 (2014) 803-808.

[26] D. Escors, M. Gato-Cañas, M. Zuazo, et al., The intracellular signalosome of PD-L 1 in cancer cells, Sig Transduct. Target. Ther. 3 (2018) 26.

[27] W.Y. Lai, B.T. Huang, J.W. Wang, P.Y. Lin, P.C. Yang, A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects, Mol. Ther. Nucleic Acids 5 (2016) e397.

[28] P. Tan, L. He, C. Xing, J. Mao, X. Yu, M. Zhu, L. Diao, L. Han, Y. Zhou, M.J. You, H.Y. Wang, R.F. Wang, Myeloid loss of Beclin 1 promotes PD-L1hi precursor B cell lymphoma development, J. Clin. Invest. 129 (2019) 5261-5277.

[29] S.C. Casey, L. Tong, Y. Li, R. Do, S. Walz, K.N. Fitzgerald, A.M. Gouw, V. Baylot, I. Gütgemann, M. Eilers, D.W. Felsher, MYC regulates the antitumor immune response through CD47 and PD-L1, Science 352 (2016) 227-231.